Different from the initially unsuccessful trials of EGFR inhibitors in nongenotyped patients, data from multiple phase III trials show superiority of gefitinib/erlotinib over standard chemotherapy for advanced NSCLC in terms of RR and PFS in the biomarker-selected EGFR mutation positive subgroup of patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.